Broader markets outperform; pharma shares rise for 3rd day

Image
Capital Market
Last Updated : Sep 07 2022 | 3:04 PM IST

The domestic equity benchmark traded with minor losses in mid-afternoon trade. The Nifty traded below 17,650 level. Pharma shares advanced for third consecutive session. Investors remained cautious ahead of the release of the US Fed's Beige Book, which summarizes the state of the world's largest economy, due later today.

At 14:26 IST, the barometer index, the S&P BSE Sensex, was down 93.28 points or 0.16% to 59,103.71. The Nifty 50 index lost 16.10 points or 0.09% to 17,639.50.

In the broader market, the S&P BSE Mid-Cap index rose 0.37% while the S&P BSE Small-Cap index advanced 0.64%.

Among the broader marker stocks, Vakrangee (up 14.87%), EIH (up 8.80%), Vodafone Idea (up 8.20%), Wockhardt (up 7.83%) and Container Corporation of India (up 7.78%) were the top gainers.

Concurrently, GMM Pfaudler (down 5.72%), Sunteck Realty (down 4.73%), HOME First Finance Company India (down 3.27%), Welspun Corp (down 2.87%) and Dhani Services (down 2.47%) were the top losers.

The market breadth was strong. On the BSE, 2063 shares advanced and 1324 shares declined. A total of 145 shares were unchanged.

Numbers to Track:

The yield on India's 10-year benchmark federal paper was currently flat at 7.179.

In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 79.8825, compared with its close of 79.8275 during the previous trading session.

MCX Gold futures for 5 October 2022 settlement lost 0.01% to Rs 50,277.

The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.09% to 110.31.

In the commodities market, Brent crude for November 2022 settlement fell 34 cents or 0.37% to $92.49 a barrel.

Buzzing Index:

The Nifty Pharma index rose 0.80% to 12,698.85. The index has added 1.54% in three sessions.

Granules India (up 2.71%), Biocon (up 1.64%), Lupin (up 1.39%), Glenmark Pharmaceuticals (up 1.38%) and Gland Pharma (up 1.23%) were the top gainers.

Among the other gainers were Torrent Pharmaceuticals (up 0.99%), Cipla (up 0.98%), Aurobindo Pharma (up 0.93%), Zydus Lifesciences (up 0.77%) and Pfizer (up 0.72%).

Stocks in Spotlight:

Coal India (CIL) advanced 2%. The government-owned coal miner said that its production increased by 44.6 million tonnes (MTs) in just 5 months and 4 days of the ongoing fiscal, as of 4 September, eclipsing the previous best of 44.5 MTs registered in FY'16, which though was for the entire year.

Spandana Sphoorty Financial slipped 2.19%. The micro financier said that its board has approved the issuance of 400 secured, senior, redeemable, transferable, listed, principal protected, market linked, rated, non-convertible debentures of face value of Rs 10 lakh each, aggregating up to Rs 40 crore, with a green shoe option of up to Rs 20 crore, on a private placement basis.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 07 2022 | 2:28 PM IST

Next Story